Compagnie de l'Odet : Combined General Meeting of June 17, 2025
June 17, 2025
Combined General Meeting of June 17, 2025
ALL THE RESOLUTIONS WERE ADOPTED BY MORE THAN 99%
DIVIDEND UP 10%
The Combined General Meeting of Compagnie de l'Odet was held on June 17, 2025, chaired by Vincent Bolloré.
92.49% of the capital took part in the voting. All the resolutions submitted to the Combined General Meeting were approved by between 99% and 100%.
Among the resolutions put to the vote at the Combined General Meeting of June 17, 2025, shareholders approved the renewal of the directorships of Gilles Alix, Cyrille Bolloré, Sébastien Bolloré, Vincent Bolloré, Yannick Bolloré, Ingrid Brochard, Cédric de Bailliencourt, Hubert Fabri, Janine Goalabré, Lynda Hadjadj, Valérie Hortefeux, Alain Moynot and Martine Studer.
The dividend of 4.40 euros per share, up 10% on the dividend paid in 2024, will be paid on June 26.
Attachment
Communiqué AG 2025 Odet 2025-06-17_ANG
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Integral Diagnostics Limited's (ASX:IDX) Stock Going Strong But Fundamentals Look Weak: What Implications Could This Have On The Stock?
Integral Diagnostics' (ASX:IDX) stock is up by a considerable 8.3% over the past month. However, in this article, we decided to focus on its weak fundamentals, as long-term financial performance of a business is what ultimately dictates market outcomes. In this article, we decided to focus on Integral Diagnostics' ROE. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In simpler terms, it measures the profitability of a company in relation to shareholder's equity. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. How To Calculate Return On Equity? ROE can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Integral Diagnostics is: 0.8% = AU$5.7m ÷ AU$693m (Based on the trailing twelve months to December 2024). The 'return' refers to a company's earnings over the last year. One way to conceptualize this is that for each A$1 of shareholders' capital it has, the company made A$0.01 in profit. See our latest analysis for Integral Diagnostics What Has ROE Got To Do With Earnings Growth? We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features. Integral Diagnostics' Earnings Growth And 0.8% ROE As you can see, Integral Diagnostics' ROE looks pretty weak. Even when compared to the industry average of 3.8%, the ROE figure is pretty disappointing. Therefore, it might not be wrong to say that the five year net income decline of 50% seen by Integral Diagnostics was possibly a result of it having a lower ROE. However, there could also be other factors causing the earnings to decline. For example, the business has allocated capital poorly, or that the company has a very high payout ratio. Next, when we compared with the industry, which has shrunk its earnings at a rate of 19% in the same 5-year period, we still found Integral Diagnostics' performance to be quite bleak, because the company has been shrinking its earnings faster than the industry. Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. Doing so will help them establish if the stock's future looks promising or ominous. Is Integral Diagnostics fairly valued compared to other companies? These 3 valuation measures might help you decide. Is Integral Diagnostics Making Efficient Use Of Its Profits? Integral Diagnostics' declining earnings is not surprising given how the company is spending most of its profits in paying dividends, judging by its three-year median payout ratio of 58% (or a retention ratio of 42%). With only a little being reinvested into the business, earnings growth would obviously be low or non-existent. You can see the 3 risks we have identified for Integral Diagnostics by visiting our risks dashboard for free on our platform here. Additionally, Integral Diagnostics has paid dividends over a period of nine years, which means that the company's management is rather focused on keeping up its dividend payments, regardless of the shrinking earnings. Upon studying the latest analysts' consensus data, we found that the company is expected to keep paying out approximately 64% of its profits over the next three years. Regardless, the future ROE for Integral Diagnostics is predicted to rise to 12% despite there being not much change expected in its payout ratio. Conclusion Overall, we would be extremely cautious before making any decision on Integral Diagnostics. The company has seen a lack of earnings growth as a result of retaining very little profits and whatever little it does retain, is being reinvested at a very low rate of return. That being so, the latest industry analyst forecasts show that the analysts are expecting to see a huge improvement in the company's earnings growth rate. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Keppel's (SGX:BN4) Shareholders May Want To Dig Deeper Than Statutory Profit
Explore Keppel's Fair Values from the Community and select yours The recent earnings posted by Keppel Ltd. (SGX:BN4) were solid, but the stock didn't move as much as we expected. We think this is due to investors looking beyond the statutory profits and being concerned with what they see. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. How Do Unusual Items Influence Profit? For anyone who wants to understand Keppel's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from S$431m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And, after all, that's exactly what the accounting terminology implies. Keppel had a rather significant contribution from unusual items relative to its profit to June 2025. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Our Take On Keppel's Profit Performance As we discussed above, we think the significant positive unusual item makes Keppel's earnings a poor guide to its underlying profitability. For this reason, we think that Keppel's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. But at least holders can take some solace from the 19% EPS growth in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So while earnings quality is important, it's equally important to consider the risks facing Keppel at this point in time. Our analysis shows 3 warning signs for Keppel (1 is a bit unpleasant!) and we strongly recommend you look at these before investing. This note has only looked at a single factor that sheds light on the nature of Keppel's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate
Explore Rhythm Biosciences's Fair Values from the Community and select yours Just because a business does not make any money, does not mean that the stock will go down. Indeed, Rhythm Biosciences (ASX:RHY) stock is up 181% in the last year, providing strong gains for shareholders. But while history lauds those rare successes, those that fail are often forgotten; who remembers Given its strong share price performance, we think it's worthwhile for Rhythm Biosciences shareholders to consider whether its cash burn is concerning. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Does Rhythm Biosciences Have A Long Cash Runway? A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at December 2024, Rhythm Biosciences had cash of AU$4.5m and no debt. In the last year, its cash burn was AU$2.1m. That means it had a cash runway of about 2.1 years as of December 2024. That's decent, giving the company a couple years to develop its business. You can see how its cash balance has changed over time in the image below. Check out our latest analysis for Rhythm Biosciences How Is Rhythm Biosciences' Cash Burn Changing Over Time? In the last year, Rhythm Biosciences did book revenue of AU$3.2m, but its revenue from operations was less, at just AU$1.5m. Given how low that operating leverage is, we think it's too early to put much weight on the revenue growth, so we'll focus on how the cash burn is changing, instead. Notably, its cash burn was actually down by 75% in the last year, which is a real positive in terms of resilience, but uninspiring when it comes to investment for growth. Admittedly, we're a bit cautious of Rhythm Biosciences due to its lack of significant operating revenues. So we'd generally prefer stocks from this list of stocks that have analysts forecasting growth. How Hard Would It Be For Rhythm Biosciences To Raise More Cash For Growth? While we're comforted by the recent reduction evident from our analysis of Rhythm Biosciences' cash burn, it is still worth considering how easily the company could raise more funds, if it wanted to accelerate spending to drive growth. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate). Rhythm Biosciences' cash burn of AU$2.1m is about 2.8% of its AU$77m market capitalisation. So it could almost certainly just borrow a little to fund another year's growth, or else easily raise the cash by issuing a few shares. How Risky Is Rhythm Biosciences' Cash Burn Situation? It may already be apparent to you that we're relatively comfortable with the way Rhythm Biosciences is burning through its cash. For example, we think its cash burn reduction suggests that the company is on a good path. And even its cash runway was very encouraging. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash. Separately, we looked at different risks affecting the company and spotted 6 warning signs for Rhythm Biosciences (of which 2 are a bit concerning!) you should know about. Of course Rhythm Biosciences may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
